| Recruiting | 1/2 | 232 | US | Gocatamig, HPN328, MK-6070, Atezolizumab, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Daiichi Sankyo | Small-Cell Lung Cancer, Neuroendocrine Carcinoma | 06/27 | 06/27 | | |
NCT06780137: A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) |
|
|
| Recruiting | 1/2 | 138 | RoW | Gacatamig, HPN328, MK-6070, Ifinatamab Deruxtecan (I-DXd), DS-7300a, MK-2400 | Merck Sharp & Dohme LLC, Daiichi Sankyo | Small Cell Lung Cancer | 10/28 | 10/28 | | |
